India, Nov. 9 -- ADC Therapeutics SA (ADCT), a commercial-stage biotechnology company focused on antibody-drug conjugates (ADCs), reported third-quarter 2026 financial results Monday, with higher ZYNLONTA product revenue and a narrower net loss.
The company also highlighted progress in strengthening its balance sheet, expanding ZYNLONTA's clinical development and advancing its potential commercialization in Japan.
Third-Quarter 2026 Financial Results
Net product revenue increased 33% year over year to $21.0 million from $15.8 million in the third quarter of 2025, primarily driven by higher sales volume.
License revenue and royalties were $0.7 million for the quarter, unchanged from the prior-year period.
Research and development expens...